Spero Therapeutics, Inc. (SPRO) Net margin 2016–2025
Spero Therapeutics, Inc. (SPRO) net profit margin by fiscal year — reported net income divided by reported revenue.
68.1%FY2025 · since FY2016: -7609.3% → 68.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 68.1% | +18549.5 pp |
| FY2024 | -18481.4% | -20925.8 pp |
| FY2023 | 2444.4% | +4298.7 pp |
| FY2022 | -1854.4% | +1070.7 pp |
| FY2021 | -2925.1% | +27423.8 pp |
| FY2020 | -30348.8% | -29064.6 pp |
| FY2019 | -1284.3% | -232.8 pp |
| FY2018 | -1051.4% | +906.3 pp |
| FY2017 | -1957.7% | +5651.5 pp |
| FY2016 | -7609.3% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice